Answers are grounded in this paper and cite their sources.
This paper discusses strategies to optimize the use of renin-angiotensin-system inhibitors for cardiorenal protection in patients with chronic kidney disease.
For more than 2 decades, the agents inhibiting the renin-angiotensin-system (RAS) form the basic pillar of therapy to offer cardiorenal protection in patients with chronic kidney disease (CKD), ...
No takes yet. Share an insight, caveat, or question.
Georgianos et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: